Mangalore Refinery And Petrochemicals Ltd (MRPL) Q1 FY27 Results Analysis: Revenue Doubles, Margin Pressure Persists
CompoundingAI Research
Updated July 15, 2026
2 min read
Neutral
Mangalore Refinery And Petrochemicals Ltd's Q1 FY27 numbers came in mixed. Here's a quick read of what worked, what to watch, and what management said.
Quick Details| Results date | July 15, 2026 |
|---|
| Quarter | Q1 FY 2026-2027 |
|---|
| Revenue (Q1) | Rs. 41,608.96 Cr (+98.25% YoY) |
|---|
| PAT (Q1) | Rs. 945.68 Cr |
|---|
| EBITDA margin | 4.37% (+351 bps YoY) |
|---|
| EPS (Q1) | Rs. 5.40 |
|---|
| Market cap | Rs. 27,640.24 Cr |
|---|
| CMP | Rs. 157.70 |
|---|
Quarter Snapshot
Revenue doubled YoY to Rs.41,609 Cr on throughput recovery, and PAT swung from a loss to Rs.946 Cr. However, EBITDA margin compressed QoQ to 4.37% due to higher crude costs. Debt reduced sharply by Rs.2,771 Cr, and a lower tax regime boosted earnings. Board governance non-compliance and margin pressure are key concerns.
Key Investment Insights
Key Positives
- Revenue grew 98.25% YoY to Rs.41,608.96 Cr, driven by recovery from prior-year turnaround shutdown.
- PAT swung from a loss of Rs.270.66 Cr in Q1FY26 to a profit of Rs.945.68 Cr in Q1FY27.
- Total borrowings reduced by Rs.2,771 Cr QoQ to Rs.11,562.56 Cr; debt-to-equity improved to 0.76x from 1.01x.
- Effective tax rate reduced to 24.08% from ~52% in FY26 due to new tax regime, providing a structural tailwind.
- Exceptional income of Rs.471.76 Cr from favorable CESTAT order (one-time).
Risk Factors
- EBITDA margin compressed from 6.25% in Q4FY26 to 4.37% in Q1FY27, indicating margin pressure.
- Cost of materials consumed rose to 84.70% of revenue from 72.30% YoY, reflecting elevated crude costs.
- Board composition non-compliance flagged by auditor (lack of independent directors).
- Exceptional income inflates reported PAT; normalized PAT of Rs.587.52 Cr is lower than reported Rs.945.68 Cr.
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now